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Background:Obesity changes body composition including fat free mass (FFM), regarded as the “pharmacologically active mass”.
Scaling drug doses to obese patients by total body mass (TBM) results in overdose. We aimed to determine the success rate of
inducing anaesthesia in normal, overweight and obese patients with propofol, using an adjusted body mass scalar (ABM), which
embodies the increased FFM of obese patients.
Methods: Ninety-six patients were divided into three groups according to body mass index (BMI): normal, overweight and
obese. Propofol 2 mg/kg ABM was administered according to the equation: ABM = IBM + 0.4(TBM – IBM), where IBM = ideal
body mass. Induction success was assessed clinically and by electroencephalographic spectral entropy.
Results: The groups were similar regarding gender, age, height and IBM. One patient was morbidly obese (BMI = 44). State
entropy (SE) decreased to < 60 in 33/33, 28/29 and 33/34 patients in the normal-weight, overweight and obese groups
respectively, an overall success rate of 97.5% (95% confidence interval 92.7% to 99.4%). Median lowest achieved SE values
and median times that SE remained < 60 did not differ between groups, however the individual values ranged widely in all
three groups. Induction failed in the two patients whose SE did not decrease to < 60 (one overweight and one obese).
Conclusions: The ABM-based propofol induction dose has a high success rate in normal, overweight and obese patients. Further
studies are required to determine the feasibility among morbidly obese patients.
Keywords: administration and dosage, body mass index, body compositions, propofol
Introduction
Obesity alters body composition and physiology.1,2 Forbes and
Welle demonstrated that as much as 40% of the excess mass
of obese individuals results from increased fat free mass (FFM).3
Intravenous drug doses scaled according to total body mass
(TBM) can result in overdosing obese individuals. Considering
that FFM can be regarded as the “pharmacologically active
mass”4 an adjusted body mass scalar (ABM) has been proposed
that accounts for the increased FFM of obese individuals by
adding 40% of excess body mass to ideal body mass (IBM), thus:
ABM = IBM+ 0.4(TBM – IBM) (1)
Our primary aim was to determine whether propofol bolus
doses scaled according to ABM, would reliably induce anaesthe-
sia in normal, overweight, and obese patients, as measured clini-
cally and by electroencephalographic spectral entropy. We
hypothesised that the proportions of patients in whom induc-
tion was successful would not differ significantly between
normal, overweight, and obese patients.
Methods
The institutional ethics review board approved this prospective
observational study set in a central teaching hospital (Project
number 197/2012). Informed consent was obtained from partici-
pants who were American Society of Anesthesiologists (ASA)
Physical Status Classification grade I or II, aged 18-70 years
and scheduled for elective surgery. Exclusion criteria were pro-
pofol allergy, compromised airway, hypotension, unstable
cardiovascular disease, and chronic sedative medication.
Patients were allocated to three different BMI categories:
Group N (22 to <25 kg/m2); Group OW (25 to < 30 kg/m2);
Group O (> 30 kg/m2).
No premedication was prescribed. Spectral entropy electrodes
(GE medical, Instrumentarium, Helsinki, Finland) were applied
to participants’ foreheads according to manufacturer instruc-
tions. Response entropy (RE) and state entropy (SE) were
recorded whilst awake (RE1 and SE1). Ringer lactate solution
15 ml/kg ABM was infused during 10 minutes. After preoxygena-
tion, propofol 2 mg/kg ABM was administered over approxi-
mately 45 seconds. After loss of consciousness, ventilation was
maintained manually using an 80% inspiratory oxygen concen-
tration. IBM in Equation 1 was calculated as follows:
IBM (men) = 22.2 × height(m)2 (2)
IBM (women) = 21.9 × height(m)2 (3)
Lowest values for response entropy (RE2) and state entropy (SE2)
were recorded. An SE of < 60 has been shown to indicate mean-
ingful hypnosis and low probability of consciousness.5,6 If SE
decreased to < 60, the time to return to > 60 was recorded. At
SE2, the success of induction of anaesthesia was assessed clini-
cally, by recording responses to name calling, touch and instruc-
tions to open the eyes.7 After SE had returned to > 60, the
planned maintenance anaesthesia was administered. If SE
failed to decrease to < 60 but the patient was clinically uncon-
scious, anaesthesia was continued as above. If SE did not
decrease to < 60 and the patient was responsive or confused,
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additional propofol was titrated to effect using 20 mg boluses.
Heart rate (HR) and mean arterial blood pressure (BPM) were
recorded before induction (HR1 and BPM1) and approximately
coinciding with RE2 and SE2 (HR2 and BPM2). All inductions
and assessments were performed by the same investigator (FXJ).
Statistical considerations
Sample size
An expected linearly decreasing trend regarding the proportions
of successful inductions of 0.125 between groups (0.95, 0.825,
0.70) was regarded as clinically important. Employing a one-
sided chi-squared test for trend at a significance level of 0.05
requires a sample size of 32 per group (nQuery Version 8.2.1.0,
Statistical Solutions, Boston, MA).
Data analysis
Statistical analysis was conducted using Stata ii software (Stata-
Corp LLC, TX, USA). A one-sided chi-squared test was used to test
for a trend regarding successful inductions between groups.
Considering that most variables were not normally distributed,
continuous data were analysed using the Kruskal- Wallis non-
parametric analysis of variance test, followed post-hoc by
Dunn’s all-pairwise comparisons. Associations were investigated
using the Spearman rank correlations test.
Results
Complete data were obtained from 96 of 98 recruited patients;
33, 29 and 34 in Group N, Group OW and Group O respectively.
Summary statistics are presented in Tables 1, 2 and 3.
Group O’s BMI ranged from 30 to 44 kg/m2. Only one patient was
morbidly obese. Groups were similar regarding gender, age,
height and IBM (Table 1). Median ABM and FFM8 differed signifi-
cantly between Group N and Group O (N < O), but not between
Group N and Group OW and not between Group OW and Group
O (Table 1, Figure 1).
The median administered propofol doses differed significantly
between Groups N and O, but not between Groups N and OW
and not between Groups OW and O. Median doses per TBM dif-
fered significantly between groups with Group N > OW > O
(Table 2, Figure 2).
Median RE and SE did not differ between groups; neither before,
nor after induction of anaesthesia (Table 2). SE decreased to <60
in 33/33, 28/29 and 33/34 patients in Groups N, OW and O
respectively (p = 0.6), all of whom lost consciousness. Induction
failed clinically in two patients, one each in Groups OW (RE2 =
91; SE2 = 85) and O (RE2 = 97; SE2 = 88), Figure 3). The overall
success ratewas 97.5% (95% confidence interval 92.7% to 99.4%).
The median times that SE remained < 60 did not differ between
groups (p > 0.9) (Table 2, Figure 4). These times ranged from 3 to
480, 0 to 640 and 0 to 302 seconds in Groups N, OW and O
respectively. The SE2 values of the two Group N patients who
had SE < 60 for only 3 seconds were 55 and 50.
Haemodynamic data are presented in Table 3. Median HR1 was
significantly higher in Group O than in Group N (p = 0.02), but
HR2 did not differ significantly between groups (p = 0.2). The
median changes in HR differed significantly between groups
(p = 0.02); groups N and OW and groups OW and O did not
differ significantly, but changed significantly more in Group N
than in Group O. Neither BPM1 (p = 0.7), BPM2 (p = 0.8) nor the
change of BPM (p = 0.6) differed significantly between groups.
SE2 values ranged widely (7 to 88). Considering that patients
were not premedicated, the possibility of stress-induced sym-
pathetic nervous system activity and an increased resting
Table 1: Biographical variables
Group N Group OW Group O
Variable Median (IQR) Median (IQR) Median (IQR) p
Gender (Male/Female) 23/10 20/9 19/15 0.4
Age (years) 49 (37;59) 47 (37;59) 43 (37;58) 0.7
TBM (kg) 68 (63;73) 80 (72;88) 93 (86;104) < 0.001*
Height (m) 1.71 (1.60;1.75) 1.72 (1.65;1.79) 1.70 (1.63;1.80) 0.5
BMI (kg/m2) 23.3 (22.0;24.2) 26.7 (26.0;27.5) 32.8 (31.2;35.4) < 0.001*
IBM (kg) 64 (62;68) 64 (60;72) 64 (59;72) 0.4
ABM (kg) 65 (62;70) 71 (65;77) 75 (69;78) < 0.001§
FFM (kg) 52.4 (44.0;56.3) 57.5 (47.7;63.8) 60.7 (47.6;70.2) 0.02§
Mass of fat (kg) 15.7 (13.4;22.1) 23.0 (19.7;27.0) 36.0 (30.2;42.2) < 0.001*
Percentage of body fat 21.9 (20.3;35.0) 26.3 (24.6;39.0) 37.2 (31.4;45.6) < 0.001*
FFM (Fat free mass) was calculated according to the formulae of Janmahasatian et al.8 Mass of fat = TBM – FFM. Percentage of fat = 100(Mass of
fat/TBM)
Dunn’s All-Pairwise Comparisons Test: * N < OW < O; § N < O;
Figure 1: Relationship (over Groups N, OW and O) between BMI and total
TBM, ABM, FFM (according to formulae by Janmahasatian et al.8), TBM
Total body mass; ABM adjusted body mass; Fat free mass; Mass of fat
= TBM – FFM
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cardiac output influencing the success of induction was con-
sidered. The rate pressure product (RPP) has been used as an
indicator of sympathetic activity.9 We calculated the RPP (SBP
× HR) before induction (RPP1). We could not demonstrate an
association between RRP1 and SE2 and between the times
that SE2 was less than 60.
Discussion
The results confirm our hypothesis that the proportion of patients
in the three BMI groups who underwent successful induction of
anaesthesia, would not differ. Furthermore, the overall success
rate exceeded 95% with a small confidence interval. The dose
range per TBM among all subjects ranged from 1.4 mg/kg to
2.0 mg/kg. If we had scaled our doses according to TBM, the
two patients in whom induction failed, would have received 10
mg more (136 mg instead of 126 mg) and 26 mg more (164
mg instead of 138mg) propofol, respectively. We can only specu-
late whether induction would have succeeded had they received
the small additional amounts.
Cardiac output is distributed mainly to the FFM which has
been described as the “pharmacologic active mass”. As TBW
increases with increasing obesity, so does FFM, but this does
not happen in parallel. Figure 1 depicts how (over Groups N,
OW and O) TBM, mass of fat and FFM increased as BMI
increases. FFM increases at a slower rate than mass of fat,
therefore doses scaled according to TBM are likely to overdose
obese patients. Conversely, ABM increases in parallel with FFM,
therefore it can be reasoned that ABM is an appropriate
dosing scalar for obese patients. The graph also shows that
dose-scaling according to FFM may work equally well but
would require a different dose/kg multiplier. Ingrande et al.
titrated propofol until loss of consciousness to normal-
weight patients and to morbidly obese patients.10 The mean
propofol dose per TBW of the normal-mass patients (2.57
mg/kg) was similar to the mean dose per FFM of the morbidly
obese patients (2.76 mg/kg). A weakness of our study is that
only one patient was morbidly obese (BMI ≥ 40 kg/m2). There-
fore it is unknown whether bolus dose-scaling according to
ABM is generally applicable to morbidly obese patients, in
spite of successful induction of anaesthesia in this single
patient. Considering that the ABM parallels increasing FFM in
the morbidly obese, we speculate that dose-scaling according
to ABM may also be applicable to otherwise healthy non-sar-
copaenic morbidly obese patients.
Figure 3: Lowest SE after induction. 1 Group N, 2 Group OW, and 3 Group
O Groups did not differ significantly (p = 0.6480). ‘*’ are extreme values
and ‘o’ are probably outliers.
Table 2: Propofol dose per total body mass (mg/kg) and entropy
Group N Group OW Group O
Variable Median (IQR) Median (IQR) Median (IQR) p
Dose (mg) 130 (124;140) 142 (130;154) 149 (138;172) < 0.001
Dose per TBM (mg/kg) 1.94 (1.88;1.97) 1.78 (1.77;1.83) 1.60 (1.53;1.65) < 0.001
RE1 97 (95;98) 97 (96;99.0) 98.0 (96;99) 0.4
SE1 87 (85;90) 88 (85;91) 89 (87;91) 0.6
RE2 25 (20;37) 23(17;35) 22 (17;34) 0.5
SE2 22 (17;32) 22 (14;31) 20 (16;31) 0.6
SE2 < 60 33/33 28/29 33/34 0.6
Time SE2 < 60 (s) 96 (43;207) 129 (35;177) 113 (58;190) 1.0
SE < 60 for < 30 s 6/33 7/29 6/34 0.8
Figure 2: Propofol dose per total body mass. TBM Total body mass; 1 =
Group N, 2 = Group OW, and 3 = Group O. Groups differed significantly (p
< 0.0001).
Figure 4: Duration of SE2 < 60. 1 Group N, 2 Group OW, and 3 Group
O. Groups did not differ significantly (p = 1.0). ‘*’ are extreme values.
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Dose scaling according to ABM should be applied with caution
to patients with sarcopaenic obesity who have increased fat
mass and decreased muscle mass. They may be elderly individ-
uals with comorbidities, including cardiac failure11 and Cushing
syndrome. Indiscriminate ABM-dosing may result in overdose.
Conversely, muscular individuals have increased FFM and low-
fat mass, thus ABM-dosing may result in unsuccessful induction
of anaesthesia.
As far as we know, our study is the first in which the ABM
equation of Forbes and Welle3 has been applied to propofol
bolus dosing. The ABM has previously been applied to dose-
scaling of propofol infusion rates administered to obese patients
by manual control12 and by target control13,14 with varying
degrees of success. However, with regard to propofol infusions,
allometric scaling of pharmacokinetic parameters has recently
proved to be superior.15
Drug concentration-time profiles during the first few minutes
that follow rapid intravenous injection cannot be described by
the multicompartment, mammillary pharmacokinetic models
that are successfully employed in target-controlled infusion
pumps.16 Several shortcomings include the assumption that
the central apparent volume of distribution is a “well stirred”
compartment into which drug is instantaneously distributed
upon injection. In reality, the events are more complex.17,18
During the first few minutes drug is progressively diluted as it
flows within the venous system and is mixed within the
central circulation, from which it exits in the arterial blood. The
arterial system distributes drug to various organs which take
up drug to varying extent (including the targeted organ, e.g.
brain). Thereafter drug is recirculated via the venous system.
The central circulation may include elements that delay the
passage of drugs by temporarily retaining and releasing drug
(e.g. the lungs). The study of these early events is known as
“front-end kinetics”19 and the concentration-time profiles are
similar in appearance to those obtained during measurement
of cardiac output by dye-dilution. These phenomena have
been successfully modelled by “hybrid” pharmacokinetic
models that incorporate into multicompartment models, physio-
logical elements such as cardiac output and recirculation.18,20
Similar to measurement of cardiac output by dye-dilution, peak
arterial drug concentrations and areas under concentration-time
curves following bolus dosing are diminished by increased
cardiac output and vice versa during low cardiac output states.
Obesity is associated with increasing resting cardiac output.21–
25 For example, cardiac output is increased by approximately
1.4 l/min by a BMI increase from 22 to 40 kg/m2.26 Considering
that cardiac output is mainly distributed to the FFM, it is likely
that the ABM-scaling equation compensates for the increased
cardiac output of overweight and obese patients. We surmised
that certain of our unpremedicated patients could have been
anxious with high pre-induction sympathetic activity, which
would partially explain the wide-ranging SE data. However,
there was no association between RPP and SE findings. This is
unsurprising considering that that RPP is not a reliable indicator
of sympathetic activity.27–29
Injection rates prominently influence early drug concentration-
time profiles and dose requirements.30–34 Rapid rates result in
high peak arterial concentrations, increased duration of effect
and vice versa. Unfortunately, we did not strictly standardize
administration rate of propofol, and this may have been partly
responsible for the wide-ranging SE data. Anaesthesiologists’
abilities to estimate the times during which they administer
induction doses are remarkably inaccurate.30 We surmise that
in clinical practice there are few anaesthesiologists who routi-
nely time their propofol induction doses. Thus, it is likely that
ABM- scaling has a high success rate as practised clinically.
Levels of hypnosis can be assessed clinically by assessing respon-
siveness and by interpreting the processed EEG. We employed
clinical assessment (request to keep the eyes open) and spectral
entropy (SE). SE has been validated to monitor the degree of hyp-
nosis caused by intravenous anaesthetic agents and by volatile
anaesthetic agents.5,35–39 A SE < 60 depicts meaningful hypno-
sis.40,41 Induction was clinically successful in all our patients
whose SE decreased to < 60. An SE < 87 indicates progressive
sedation with propofol,42 and emergence from anaesthesia
usually occurs when SE > 90. Vakkuri et al. observed recovery of
consciousness at SE 73 (95% CI 67.4 to 78.6) after induction
with propofol 2 mg/kg administered during 20 seconds.5 We
chose a SE threshold of 60 as an indication of adequate hypnosis
since this is the level that is generally accepted as being appropri-
ate to perform surgery.5,6 The interquartile ranges during which
SE remained < 60 in Groups N, OW and Owere 43 to 207 seconds,
45 to 194 seconds, and 58 to 190 seconds, respectively. These
times were sufficient to conduct uncomplicated airway manage-
ment. Times for SE to return to > 73 would be even longer and
would still probably ensure amnesia if airway management
required more time than usual. Taking these factors into
account, we are of the opinion that reliable induction was
achieved in all, except two patients.
HR and BPM changes were mild in all three groups and the
median differences were clinically unimportant. The changes
were recorded at the time of SE2. It has been shown that follow-
ing propofol induction, maximum blood pressure declines
follow some minutes after the EEG nadir.43 It is unknown
whether our recorded changes were the greatest that our
patients experienced.
We conclude that scaling propofol induction doses according to
the ABM of Forbes and Welle had a high success rate in normal-
Table 3: Blood pressure and heart rate
Group N Group OW Group O
Variable Median (IQR) Median (IQR) Median (IQR) p
BPM1(mm Hg) 105.0 (93.8;115.7) 109.7 (94.5;122.5) 104.0 (97.6;116.0) 0.7
HR1(beats/min) 72.0 (64.0;84.0) 77.0 (68.0;95.5) 87.5 (75.0;99.0) 0.02
BPM2 92.3 (81.17;102.5) 89.7 (84.2;102.8) 92.3 (81.2;102.5) 0.8
HR2 85.0 (71.5;100.0) 86.0 (74.5;93.0) 91.0 (81.0;100.5) 0.2
BPM change (%) -15.2 (-23.4;-3.4) -15.0 (-24.2;-5.4) -11.8 (-20.7;-3.4) 0.6
HR change (%) 13.6 (7.1;27.8) 8.1 (0;13.7) 4.6 (-2.1;13.6) 0.02
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mass, overweight and obese, ASA I and II patients. We did not
detect significant differences in median duration of uncon-
sciousness or maximum electroencephalographic depression.
Further research is required to establish whether ABM-scaling
can be applied to morbidly obese patients.
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